Advanced search
Publication Cover
Leukemia & Lymphoma Volume 57, 2016 - Issue 6
Submit an article Journal homepage
509
Views
20
CrossRef citations to date
0
Altmetric
Letters to the Editor

A phase II study of AT9283, an aurora kinase inhibitor, in patients with relapsed or refractory multiple myeloma: NCIC clinical trials group IND.191

Annette E. HayNCIC Clinical Trials Group, Queen’s University, Kingston, ON, Canada,
,
Alli MurugesanDepartment of Biology, University of New Brunswick, Saint John, NB, Canada,
,
Ashley M. DiPasqualeDepartment of Medicine, Dalhousie University, Saint John, NB, Canada,
,
Tom KouroukisJuravinski Cancer Centre, Hamilton, ON, Canada,
,
Irwindeep SandhuDepartment of Medicine, Division of Hematology, University of Alberta, Edmonton, AB, Canada,
,
Vishal KukretiDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada,
,
Nizar J. BahlisDivision of Hematology and Hematologic Malignancies, University of Calgary, Calgary, AB, Canada,
,
Johan LateganDivision of Hematology and Hematologic Malignancies, University of Calgary, Calgary, AB, Canada,
,
Donna E. ReeceDepartment of Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada,
,
John F. LyonsAstex Pharmaceuticals, Inc., Dublin, CA, USA, and
,
Joana SederiasNCIC Clinical Trials Group, Queen’s University, Kingston, ON, Canada,
,
Hao XuNCIC Clinical Trials Group, Queen’s University, Kingston, ON, Canada,
,
Jean PowersNCIC Clinical Trials Group, Queen’s University, Kingston, ON, Canada,
,
Lesley K. SeymourNCIC Clinical Trials Group, Queen’s University, Kingston, ON, Canada,
&
Tony ReimanDepartment of Biology, University of New Brunswick, Saint John, NB, Canada, ;Department of Oncology, Saint John Regional Hospital and Department of Medicine, Dalhousie University, Saint John, NB, CanadaCorrespondence[email protected]
 show all
Pages 1463-1466 | Published online: 15 Oct 2015

References

  • Carmena M, Earnshaw WC. The cellular geography of Aurora kinases. Nat Rev Mol Cell Biol 2003; 4: 842–854.
  • Chng WJ, Braggio E, Mulligan G, et al. The centrosome index is a powerful prognostic marker in myeloma and identifies a cohort of patients that might benefit from aurora kinase inhibition. Blood 2008; 111: 1603–1609.
  • Kryukov F, Nemec P, Dementyeva E, et al. Molecular heterogeneity and centrosome-associated genes in multiple myeloma. Leuk Lymphoma 2013; 54: 1982–1988.
  • Evans R, Naber C, Steffler T, et al. Aurora A kinase RNAi and small molecule inhibition of Aurora kinases with VE-465 induce apoptotic death in multiple myeloma cells. Leuk Lymphoma 2008; 49: 559–569.
  • Evans RP, Naber C, Steffler T, et al. The selective Aurora B kinase inhibitor AZD1152 is a potential new treatment for multiple myeloma. Br J Haematol 2008; 140: 295–302.
  • Santo L, Hideshima T, Cirstea D, et al. Antimyeloma activity of a Multitargeted Kinase Inhibitor, AT9283, via potent Aurora Kinase and STAT3 Inhibition either alone or in combination with Lenalidomide. Clin Cancer Res 2011; 17: 3259–3271.
  • Dent SF, Gelmon KA, Chi KN, et al. NCIC CTG IND.181: Phase I study of AT9283 given as a weekly 24 hour infusion in advanced malignancies. Invest New Drugs 2013; 31: 1522–1539.
  • Durie BGM, Harousseau JL, Miguel JS, et al. International uniform response criteria for multiple myeloma. Leukemia 2006; 20: 1467–1473.
  • Fleming TR. One-sample multiple testing procedure for phase II clinical trials. Biometrics 1982; 38: 143–151.
  • Foran J, Ravandi F, Wierda W, et al. A Phase I and Pharmacodynamic Study of AT9283, a small-molecule inhibitor of aurora kinases in patients with relapsed/refractory leukemia or myelofibrosis. Clin Lymphoma Myeloma Leuk 2014; 14: 223–230.
  • Graux C, Sonet A, Maertens J, et al. A phase I dose-escalation study of MSC1992371A, an oral inhibitor of aurora and other kinases, in advanced hematologic malignancies. Leukemia Res 2013; 37: 1100–1106.
  • Kelly KR, Shea TC, Goy A, et al. Phase I study of MLN8237 - investigational Aurora A kinase inhibitor - in relapsed/refractory multiple myeloma, Non-Hodgkin lymphoma and chronic lymphocytic leukemia. Invest New Drugs 2014; 32: 489–499.
  • Friedberg JW, Mahadevan D, Cebula E, et al. Phase II Study of Alisertib, a Selective Aurora A Kinase Inhibitor, in Relapsed and Refractory Aggressive B- and T-Cell Non-Hodgkin Lymphomas. J Clin Oncol 2014; 32: 44–50.
  • Kantarjian HM, Sekeres MA, Ribrag V, et al. Phase I Study Assessing the safety and tolerability of Barasertib (AZD1152) with low-dose Cytosine Arabinoside in elderly patients with AML. Clin Lymphoma Myeloma Leuk 2013; 13: 559–567.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.